Also published as: A Ram Kim, Ae-Jung Kim, Ah-Ram Kim, Albert H Kim, Alison J Kim, Andrea J Kim, Angela H Kim, Angela Kim, Angela S Kim, Anna Kim, Anthony S Kim, Aram Kim, Arie Kim, B T Kim, B-Y Kim, Baek Kim, Beom-Jun Kim, Beomsoo Kim, Beomsu Kim, Bo Ri Kim, Bo Young Kim, Bo-Eun Kim, Bo-Ra Kim, Bo-Rahm Kim, Bomi Kim, Bong-Jo Kim, Bongjun Kim, Boo-Young Kim, Borahm Kim, Boram Kim, Brandon J Kim, Brian S Kim, Byeong-Won Kim, Byoung Jae Kim, Byron Kim, Byung Guk Kim, Byung Jin Kim, Byung-Chul Kim, Byung-Gyu Kim, Byung-Taek Kim, Byungwook Kim, C H Kim, Carla F Kim, Caroline Kim, Cecilia E Kim, Cecilia Kim, Chae-Hyun Kim, Chan Wook Kim, Chan-Duck Kim, Chan-Hee Kim, Chan-Wha Kim, Chang Seong Kim, Chang-Gu Kim, Chang-Yub Kim, Chanhee Kim, Cheol-Hee Kim, Cheol-Su Kim, Cheorl-Ho Kim, Choel Kim, Chong Ae Kim, Chong Kook Kim, Chongtae Kim, Choon Ok Kim, Choon-Song Kim, Chu-Young Kim, Chul Hoon Kim, Chul Hwan Kim, Chul-Hong Kim, Chunki Kim, D-W Kim, Da Sol Kim, Da-Hyun Kim, Da-Sol Kim, Dae Hyun Kim, Dae In Kim, Dae Keun Kim, Dae-Eun Kim, Dae-Jin Kim, Dae-Kyeong Kim, Dae-Kyum Kim, Dae-Soo Kim, Daeeun Kim, Daegyeom Kim, Daeseung Kim, Daesik Kim, Daham Kim, Dahee Kim, Dakyung Kim, Dan Say Kim, David E Kim, Dayoung Kim, Dennis Y Kim, Deok Ryong Kim, Deok-Ho Kim, Deokhoon Kim, Do Hyung Kim, Do Yeon Kim, Do-Hyung Kim, Do-Kyun Kim, Dokyoon Kim, Don-Kyu Kim, Dong Gwang Kim, Dong Ha Kim, Dong Hyun Kim, Dong Il Kim, Dong Joon Kim, Dong Wook Kim, Dong-Eun Kim, Dong-Hee Kim, Dong-Hoon Kim, Dong-Hyeok Kim, Dong-Hyun Kim, Dong-Ik Kim, Dong-Kyu Kim, Dong-Seok Kim, Dong-Wook Kim, Dong-Yi Kim, Dong-il Kim, Donghee Kim, Donghyeon Kim, Donghyun Kim, Dongjoon Kim, Dongkyun Kim, Dongwoo Kim, Doo Yeon Kim, Doo Yeong Kim, Doyeon Kim, Duck-Hee Kim, E Kim, E-S Kim, Edwin H Kim, Eiru Kim, Elizabeth H Kim, Ellen Kim, Eonmi Kim, Eosu Kim, Eric Eunshik Kim, Eric Kim, Esl Kim, Esther Kim, Eui Hyun Kim, Eui Jin Kim, Eui-Soon Kim, Eun Hee Kim, Eun Ho Kim, Eun Ji Kim, Eun Kim, Eun Young Kim, Eun-Jin Kim, Eun-Joo Kim, Eun-Jung Kim, Eun-Kyung Kim, Eunae Kim, Eung Yeop Kim, Eung-Gook Kim, Eungseok Kim, Eunha Kim, Eunhyun Kim, Eunjoon Kim, Eunju Kim, Eunkyeong Kim, Eunmi Kim, Gahyun Kim, Geun-Young Kim, Gi Beom Kim, Gibae Kim, Gitae Kim, Go Woon Kim, Goo-Young Kim, Goun Kim, Grace Kim, Gu-Hwan Kim, Gukhan Kim, Gunhee Kim, Gwang Sik Kim, Gwangil Kim, Gye Lim Kim, Gyeonghun Kim, Gyudong Kim, H Kim, H S Kim, Ha-Jung Kim, Ha-Neui Kim, Hae Won Kim, Haein Kim, Haelee Kim, Haeryoung Kim, Hail Kim, Han Gyung Kim, Han Young Kim, Han-Kyul Kim, Hana Kim, Hanah Kim, Hang-Rai Kim, Hannah Kim, Hark Kyun Kim, Hee Jeong Kim, Hee Jin Kim, Hee Jong Kim, Hee Nam Kim, Hee Su Kim, Hee Young Kim, Hee-Jin Kim, Hee-Sun Kim, Heebal Kim, Heegoo Kim, Heejin Kim, Hei Sung Kim, Helen B Kim, Helen Kim, Heung-Joong Kim, Ho Shik Kim, Ho-Sook Kim, Hoguen Kim, Hong Sug Kim, Hong-Gi Kim, Hong-Hee Kim, Hong-Kook Kim, Hong-Kyu Kim, Hoon Kim, Hoon Seok Kim, Howard H Kim, Hwa-Jung Kim, Hwajung Kim, Hwi Seung Kim, Hwijin Kim, Hye Jin Kim, Hye Ran Kim, Hye Ree Kim, Hye Young Kim, Hye Yun Kim, Hye-Jin Kim, Hye-Jung Kim, Hye-Ran Kim, Hye-Sung Kim, Hye-Yeon Kim, Hye-Young H Kim, Hyejin Kim, Hyelim Kim, Hyemin Kim, Hyeon Ho Kim, Hyeon Jeong Kim, Hyeon-Ah Kim, Hyeong Hoe Kim, Hyeong Su Kim, Hyeong-Geug Kim, Hyeong-Jin Kim, Hyeong-Rok Kim, Hyeong-Taek Kim, Hyeonwoo Kim, Hyeseon Kim, Hyesung Kim, Hyeung-Rak Kim, Hyeyoon Kim, Hyeyoung Kim, Hyo Jong Kim, Hyo Jung Kim, Hyo-Soo Kim, Hyojin Kim, Hyojung Kim, Hyoun Ju Kim, Hyoun-Ah Kim, Hyoung Kyu Kim, Hyuk Soon Kim, Hyun Eun Kim, Hyun Gi Kim, Hyun Joon Kim, Hyun Ju Kim, Hyun Kim, Hyun Sil Kim, Hyun Soo Kim, Hyun Sook Kim, Hyun-Ji Kim, Hyun-Jin Kim, Hyun-Jung Kim, Hyun-Kyong Kim, Hyun-Sic Kim, Hyun-Soo Kim, Hyun-Yi Kim, Hyun-Young Kim, Hyun-ju Kim, Hyunbae Kim, Hyung Bum Kim, Hyung Hoi Kim, Hyung Min Kim, Hyung Yoon Kim, Hyung-Goo Kim, Hyung-Gu Kim, Hyung-Jun Kim, Hyung-Mi Kim, Hyung-Ryong Kim, Hyung-Seok Kim, Hyung-Sik Kim, Hyung-Suk Kim, Hyungjun Kim, Hyungkuen Kim, Hyungsoo Kim, Hyunjin Kim, Hyunjoon Kim, Hyunju Kim, Hyunki Kim, Hyunmi Kim, Hyunsoo Kim, Hyunwoo Kim, Hyunwook Kim, Hyunyoung Kim, Ick Young Kim, Il-Chan Kim, Il-Man Kim, Il-Sup Kim, In Ja Kim, In Joo Kim, In Kyoung Kim, In Su Kim, In Suk Kim, In-Hoo Kim, J H Kim, J Julie Kim, J Y Kim, Jae Bum Kim, Jae Geun Kim, Jae Gon Kim, Jae Hoon Kim, Jae Hun Kim, Jae Hyoung Kim, Jae Hyun Kim, Jae Seon Kim, Jae Suk Kim, Jae T Kim, Jae-Ick Kim, Jae-Jun Kim, Jae-Jung Kim, Jae-Min Kim, Jae-Ryong Kim, Jae-Yong Kim, Jae-Yoon Kim, Jae-Young Kim, Jaegil Kim, Jaehoon Kim, Jaemi Kim, Jaeuk U Kim, Jaewon Kim, Jaeyeon Kim, Jaeyoon Kim, Jang Heub Kim, Jang-Hee Kim, Jason K Kim, Jason Kim, Jayoun Kim, Jee Ah Kim, Jeeho Kim, Jeewoo Kim, Jeeyoung Kim, Jeffrey J Kim, Jeffrey Kim, Jenny H Kim, Jeong Hee Kim, Jeong Kyu Kim, Jeong Su Kim, Jeong-Han Kim, Jeong-Min Kim, Jeonghan Kim, Jeongseon Kim, Jeongseop Kim, Jeri Kim, Jessica Kim, Jewoo Kim, Ji Eun Kim, Ji Hun Kim, Ji Hye Kim, Ji Hyun Kim, Ji Won Kim, Ji Yeon Kim, Ji Young Kim, Ji-Dam Kim, Ji-Eun Kim, Ji-Hoon Kim, Ji-Man Kim, Ji-Won Kim, Ji-Woon Kim, Ji-Young Kim, Ji-Yul Kim, Ji-Yun Kim, Jieun Kim, Jiha Kim, Jiho Kim, Jihoon Kim, Jihye Kim, Jihyun Kim, Jimi Kim, Jin Cheon Kim, Jin Gyeom Kim, Jin Hee Kim, Jin Kim, Jin Kyong Kim, Jin Man Kim, Jin Seok Kim, Jin Won Kim, Jin Woo Kim, Jin Young Kim, Jin-Chul Kim, Jin-Soo Kim, Jina Kim, Jinhee Kim, Jinho Kim, Jinkyeong Kim, Jinsoo Kim, Jinsu Kim, Jinsup Kim, Jisook Kim, Jisu Kim, Jisun Kim, Jisup Kim, Jiwon Kim, Jiyea Kim, Jiyeon Kim, Jong Deog Kim, Jong Geun Kim, Jong Han Kim, Jong Heon Kim, Jong Ho Kim, Jong Hwan Kim, Jong Won Kim, Jong Woo Kim, Jong Yeol Kim, Jong-Ho Kim, Jong-Hyun Kim, Jong-Il Kim, Jong-Joo Kim, Jong-Ki Kim, Jong-Kyu Kim, Jong-Oh Kim, Jong-Seo Kim, Jong-Seok Kim, Jong-Won Kim, Jong-Yeon Kim, Jong-Youn Kim, JongKyong Kim, Jongchan Kim, Jonggeol J Kim, Jonggeol Jeffrey Kim, Jongho Kim, Jongkyu Kim, Jongmyung Kim, Jongwan Kim, Jooho Kim, Joon Kim, Joong Sun Kim, Joong-Seok Kim, Joonki Kim, Joonseok Kim, Joonyoung Kim, Joonyoung R Kim, Joori Kim, Joseph C Kim, Joseph Han Sol Kim, Joung Sug Kim, Joungmok Kim, Ju Deok Kim, Ju Han Kim, Ju Young Kim, Ju-Kon Kim, Ju-Ryoung Kim, Ju-Wan Kim, Juhyun Kim, Jun Chul Kim, Jun Hee Kim, Jun Hoe Kim, Jun Pyo Kim, Jun Seok Kim, Jun Suk Kim, Jun W Kim, Jun-Hyung Kim, Jun-Mo Kim, Jun-Sik Kim, June Hee Kim, June Soo Kim, June-Bum Kim, Junesun Kim, Jung Dae Kim, Jung H Kim, Jung Hee Kim, Jung Ho Kim, Jung Ki Kim, Jung Oh Kim, Jung Soo Kim, Jung Sun Kim, Jung-Ha Kim, Jung-Hyun Kim, Jung-In Kim, Jung-Lye Kim, Jung-Taek Kim, Jung-Woong Kim, JungMin Kim, Jungeun Kim, Jungsu Kim, Jungwoo Kim, Juyeong Kim, Juyong B Kim, Juyoung Kim, K-K Kim, K-S Kim, Kahye Kim, Kang Ho Kim, Kangjoon Kim, Kee-Pyo Kim, Kee-Tae Kim, Kellan Kim, Keun You Kim, Kevin K Kim, Ki Hyun Kim, Ki Kwon Kim, Ki Tae Kim, Ki Woong Kim, Kil-Nam Kim, Kiyoung Kim, Kook Hwan Kim, Kwan Hyun Kim, Kwan-Suk Kim, Kwang Dong Kim, Kwang Pyo Kim, Kwang-Eun Kim, Kwang-Pyo Kim, Kwangho Kim, Kwangwoo Kim, Kwonseop Kim, Kye Hun Kim, Kye Hyun Kim, Kye-Seong Kim, Kyeong Jin Kim, Kyeong-Min Kim, Kyeongjin Kim, Kyeongmi Kim, Kyong Min Kim, Kyong-Tai Kim, Kyoung Hoon Kim, Kyoung Hwan Kim, Kyoung Oh Kim, Kyoungtae Kim, Kyu-Kwang Kim, Kyuho Kim, Kyung An Kim, Kyung Do Kim, Kyung Han Kim, Kyung Hee Kim, Kyung Mee Kim, Kyung Sup Kim, Kyung Woo Kim, Kyung-Chang Kim, Kyung-Hee Kim, Kyung-Sub Kim, Kyung-Sup Kim, Kyunga Kim, Kyunggon Kim, Kyungjin Kim, Kyungsook Kim, Kyungtae Kim, Kyungwon Kim, Leen Kim, Leo A Kim, Leo Kim, Lia Kim, Luke Y Kim, M J Kim, M Kim, M V Kim, Maya Kim, Meelim Kim, Meesun Kim, Mi Jeong Kim, Mi Kyung Kim, Mi Ok Kim, Mi Ra Kim, Mi Young Kim, Mi-Hyun Kim, Mi-Na Kim, Mi-Sung Kim, Mi-Yeon Kim, Mi-Young Kim, Mijeong Kim, Mijung Kim, Min Bum Kim, Min Cheol Kim, Min Chul Kim, Min Joo Kim, Min Ju Kim, Min Jung Kim, Min Kim, Min Kyeong Kim, Min Seo Kim, Min Soo Kim, Min Wook Kim, Min-A Kim, Min-Gon Kim, Min-Hyun Kim, Min-Seo Kim, Min-Seon Kim, Min-Sik Kim, Min-Sun Kim, Min-Young Kim, Mina K Kim, Minah Kim, Minchul Kim, Minhee Kim, Minjae Kim, Minjeong Kim, Minji Kim, Minjoo Kim, Minju Kim, Minkyeong Kim, Minkyung Kim, Minseon Kim, Minsik Kim, Minsoon Kim, Minsu Kim, Minsuk Kim, Miri Kim, Miso Kim, Misu Kim, Misun Kim, Misung Kim, Moo-Yeon Kim, Moon Suk Kim, Myeong Ji Kim, Myeong Ok Kim, Myeong-Kyu Kim, Myeoung Su Kim, Myoung Hee Kim, Myoung Ok Kim, Myoung Sook Kim, Myung Jin Kim, Myung-Jin Kim, Myung-Sun Kim, Myung-Sunny Kim, Myungshin Kim, Myungsuk Kim, Na Yeon Kim, Na-Kuang Kim, Na-Young Kim, Nam Hee Kim, Nam-Eun Kim, Nam-Ho Kim, Nam-Hyung Kim, NamDoo Kim, NamHee Kim, Namkyoung Kim, Namphil Kim, Nan Young Kim, Nari Kim, Ngoc Thanh Kim, Ngoc-Thanh Kim, Oc-Hee Kim, Oh Yoen Kim, Ohn Soon Kim, Ok Jin Kim, Ok-Hwa Kim, Ok-Hyeon Kim, Ok-Kyung Kim, Okhwa Kim, Paul H Kim, Paul Kim, Paul T Kim, Peter K Kim, Reuben H Kim, Richard B Kim, Richard Kim, Rokki Kim, Rosalind Kim, Ryung S Kim, S Kim, S Y Kim, Sae Hun Kim, Saerom Kim, Sang Chan Kim, Sang Eun Kim, Sang Geon Kim, Sang Hyuk Kim, Sang Jin Kim, Sang Ryong Kim, Sang Soo Kim, Sang Wun Kim, Sang-Gun Kim, Sang-Hoon Kim, Sang-Min Kim, Sang-Tae Kim, Sang-Woo Kim, Sang-Young Kim, Sangchul Kim, Sangmi Kim, Sangsoo Kim, Sangwoo Kim, Scott Y H Kim, Se Hyun Kim, Se-Wha Kim, Sejoong Kim, Seohyeon Kim, Seohyun Kim, Seok Won Kim, Seokhwi Kim, Seokjoong Kim, Seol-A Kim, Seon Hee Kim, Seon Hwa Kim, Seon-Kyu Kim, Seon-Young Kim, Seong Jun Kim, Seong Kim, Seong-Hyun Kim, Seong-Ik Kim, Seong-Jin Kim, Seong-Min Kim, Seong-Seop Kim, Seong-Tae Kim, Seonggon Kim, Seongho Kim, Seongmi Kim, Seonhee Kim, Seoyeon Kim, Seoyoung Kim, Serim Kim, Seul Young Kim, Seul-Ki Kim, Seulhee Kim, Seung Chul Kim, Seung Jun Kim, Seung Tea Kim, Seung Won Kim, Seung-Jin Kim, Seung-Ki Kim, Seung-Whan Kim, Seungsoo Kim, Sewoon Kim, Shi-Mun Kim, Shin Kim, Sin Gon Kim, Sinai Kim, So Ree Kim, So Yeon Kim, So Young Kim, So-Hee Kim, So-Woon Kim, So-Yeon Kim, Soee Kim, Soeun Kim, Sohee Kim, Sol Kim, Song-Rae Kim, Soo Hyun Kim, Soo Jung Kim, Soo Wan Kim, Soo Whan Kim, Soo Yoon Kim, Soo Young Kim, Soo-Hyun Kim, Soo-Rim Kim, Soo-Youl Kim, SooHyeon Kim, Sook Young Kim, Soon Hee Kim, Soon Sun Kim, Soon-Hee Kim, Soriul Kim, Soung Jung Kim, Sowon Kim, Soyeong Kim, Steve Kim, Stuart K Kim, Su Jin Kim, Su Kang Kim, Su-Hyeong Kim, Su-Jeong Kim, Su-Jin Kim, Su-Yeon Kim, Suhyun Kim, Suhyung Kim, Suji Kim, Sujin Kim, Sujung Kim, Suk Jae Kim, Suk-Jeong Kim, Suk-Kyung Kim, Sukjun Kim, Sun Hee Kim, Sun Hye Kim, Sun Woong Kim, Sun Yeou Kim, Sun-Gyun Kim, Sun-Hee Kim, Sun-Hong Kim, Sun-Joong Kim, Sung Eun Kim, Sung Han Kim, Sung Hyun Kim, Sung Kyun Kim, Sung Mok Kim, Sung Soo Kim, Sung Tae Kim, Sung Won Kim, Sung Woo Kim, Sung Yeol Kim, Sung Young Kim, Sung-Bae Kim, Sung-Eun Kim, Sung-Hee Kim, Sung-Hoon Kim, Sung-Hou Kim, Sung-Jo Kim, Sung-Kyu Kim, Sung-Mi Kim, Sung-Wan Kim, Sunggun Kim, Sunghak Kim, Sunghoon Kim, Sunghun Kim, Sunghwan Kim, Sungjoo Kim, Sungmin Kim, Sungrae Kim, Sungryong Kim, Sungup Kim, Sungyeon Kim, Sungyun Kim, Sunkyu Kim, Sunoh Kim, Sunyoung Kim, Susy Kim, Sydney Y Kim, Tae Hoen Kim, Tae Hoon Kim, Tae Hun Kim, Tae Hyun Kim, Tae Il Kim, Tae Jin Kim, Tae Min Kim, Tae Wan Kim, Tae-Eun Kim, Tae-Gyu Kim, Tae-Hyoung Kim, Tae-Hyun Kim, Tae-Mi Kim, Tae-Min Kim, Tae-Woon Kim, Tae-You Kim, TaeHyung Kim, TaeYeong Kim, Taeeun Kim, Taehyeung Kim, Taehyoun Kim, Taeil Kim, Taejung Kim, Taek-Kyun Kim, Taek-Yeong Kim, Taewan Kim, Taeyoung Kim, Tai Kyoung Kim, Un Gi Kim, Un-Kyung Kim, Vladimir Kim, Wanil Kim, William Kim, Won Dong Kim, Won Ho Kim, Won J Kim, Won Jeoung Kim, Won Kim, Won Kon Kim, Won Kyung Kim, Won Seok Kim, Won Tae Kim, Won-Tae Kim, Wondong Kim, Woo Jin Kim, Woo Kim, Woo Kyung Kim, Woo Sik Kim, Woo-Jin Kim, Woo-Kyun Kim, Woo-Shik Kim, Woo-Yang Kim, Woojin Scott Kim, Wook Kim, Woong-Ki Kim, Woonhee Kim, Wootae Kim, Wun-Jae Kim, Y A Kim, Y S Kim, Y-D Kim, Y-M Kim, Yangseok Kim, Ye-Ri Kim, Yeaseul Kim, Yeeun Kim, Yeji Kim, Yejin Kim, Yekaterina Kim, Yeon Ju Kim, Yeon-Hee Kim, Yeon-Jeong Kim, Yeon-Jung Kim, Yeon-Ki Kim, Yeong-Sang Kim, Yeonhwa Kim, Yeonjung Kim, Yeonsoo Kim, Yerin Kim, Yeseul Kim, Yeul Hong Kim, Yo-Han Kim, Yong Deuk Kim, Yong Kwan Kim, Yong Kyun Kim, Yong Kyung Kim, Yong Sig Kim, Yong Sik Kim, Yong Sook Kim, Yong Sung Kim, Yong-Hoon Kim, Yong-Lim Kim, Yong-Ou Kim, Yong-Sik Kim, Yong-Soo Kim, Yong-Wan Kim, Yong-Woon Kim, Yongae Kim, Yonghwan Kim, Yongjae Kim, Yongkang Kim, Yongmin Kim, Yoo Ri Kim, Yoojin Kim, Yoon Sook Kim, Yoongeum Kim, Yoonjung Kim, You Sun Kim, You-Jin Kim, You-Sun Kim, Youbin Kim, Youn Shic Kim, Youn-Jung Kim, Youn-Kyung Kim, Young Eun Kim, Young Hee Kim, Young Ho Kim, Young Hun Kim, Young Hwa Kim, Young Jin Kim, Young Ju Kim, Young Mi Kim, Young Nam Kim, Young Rae Kim, Young Ree Kim, Young S Kim, Young Sam Kim, Young Sik Kim, Young Tae Kim, Young Woo Kim, Young-Bum Kim, Young-Cho Kim, Young-Chul Kim, Young-Dae Kim, Young-Eun Kim, Young-Ho Kim, Young-Hoon Kim, Young-Il Kim, Young-Im Kim, Young-Jin Kim, Young-Joo Kim, Young-Mi Kim, Young-Saeng Kim, Young-Won Kim, Young-Woo Kim, Young-Woong Kim, Young-Youn Kim, Youngchang Kim, Youngchul Kim, Youngeun Kim, Younghoon Kim, Youngjoo Kim, Youngmi Kim, Youngsin Kim, Youngsoo Kim, Youngsook Kim, Youngwoo Kim, Yu Kyeong Kim, Yu Mi Kim, Yu-Jin Kim, Yul-Ho Kim, Yuli Kim, Yumi Kim, Yun Gi Kim, Yun Hye Kim, Yun Joong Kim, Yun Seok Kim, Yun-Jin Kim, Yunjung Kim, Yunkyung Kim, Yunwoo Kim
Lipoprotein(a) [Lp(a)] is a causal, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS). Although elevated Lp(a) affects app Show more
Lipoprotein(a) [Lp(a)] is a causal, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS). Although elevated Lp(a) affects approximately 20% of the global population, specific pharmacological options have long been unavailable, leaving a major gap in residual risk management. This review synthesizes current understanding of Lp(a) molecular architecture, genetics, and metabolism, and integrates mechanistic evidence linking Lp(a) to pro-atherogenic, pro-inflammatory, and pro-thrombotic pathways. We summarize epidemiological and genetic data associating Lp(a) with a broad spectrum of cardiovascular outcomes and discuss current clinical guidelines on screening and risk stratification. Furthermore, we provide an up-to-date overview of the emerging therapeutic landscape, including RNA-targeted therapies and novel oral small molecules. With pivotal phase 3 outcome trials nearing completion, the field is transitioning from viewing Lp(a) as an untreatable biomarker to an actionable therapeutic target, with important implications for precision cardiovascular prevention. Show less
Dysregulated extracellular matrix (ECM) deposition and epithelial-mesenchymal transition (EMT) in the trabecular meshwork (TM) contribute to glaucoma-associated fibrotic remodeling, and lysophosphatid Show more
Dysregulated extracellular matrix (ECM) deposition and epithelial-mesenchymal transition (EMT) in the trabecular meshwork (TM) contribute to glaucoma-associated fibrotic remodeling, and lysophosphatidic acid (LPA) potently induces these profibrotic responses in human trabecular meshwork (HTM) cells. We investigated whether an ethanolic extract of Show less
Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS), with plasma levels largely unaffected by li Show more
Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS), with plasma levels largely unaffected by lifestyle modification or conventional lipid-lowering therapy. Although international guidelines increasingly recognize Lp(a) as a risk-enhancing factor, in many Asian populations thresholds for high Lp(a) and treatment strategies remain undefined. This Korean position paper, developed by the Lp(a) Task Force of the Korean Society of Lipid and Atherosclerosis, presents an evidence-based summary of the pathophysiology, clinical relevance, and therapeutic landscape surrounding Lp(a), with a focus on Korean-specific data. It reviews the genetic architecture of Lp(a), ethnic variability in concentrations, and its mechanistic roles in inflammation, thrombosis, and calcification. Based on large Korean cohorts, a 3-tiered classification is proposed of normal (<30 mg/dL), borderline high (30-49 mg/dL), and high (≥50 mg/dL), harmonizing global thresholds with local data. The document also highlights the limitations of current Lp(a) assays in Korea, and calls for standardized, isoform-insensitive testing. Novel therapeutics, including antisense oligonucleotides, small interfering RNAs, and small molecular inhibitors, have shown promising Lp(a)-lowering effects, with multiple phase 3 trials currently ongoing, or in planning. Given the unmet clinical need, the paper recommends incorporating Lp(a) into cardiovascular risk assessment, and calls for Korean-specific longitudinal studies, national screening strategies, and participation in clinical trials. These efforts will help clarify Lp(a)-associated risk in Korean patients and guide the adoption of future targeted therapies. Show less
Lipoprotein(a) (Lp(a)) is a highly atherogenic lipoprotein and the target of investigational therapies. Using a Mendelian randomization study design, we aimed to clarify associations between genetical Show more
Lipoprotein(a) (Lp(a)) is a highly atherogenic lipoprotein and the target of investigational therapies. Using a Mendelian randomization study design, we aimed to clarify associations between genetically predicted Lp(a) levels and cerebrovascular disease outcomes and related phenotypes. We obtained genetic associations with Lp(a) levels ( Genetically predicted Lp(a) levels associated with significantly increased risk of all-cause ischemic stroke (odds ratio [OR], 1.04 [95% CI, 1.02-1.07], Elevated Lp(a) is primarily associated with ischemic stroke due to large artery atherosclerosis, while showing no link to cerebral small vessel disease. These findings support prioritization of patients with atherosclerotic cerebrovascular disease in Lp(a)-lowering stroke prevention trials. Show less
Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS), with plasma levels largely unaffected by li Show more
Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS), with plasma levels largely unaffected by lifestyle modification or conventional lipid-lowering therapy. Although international guidelines increasingly recognize Lp(a) as a risk-enhancing factor, in many Asian populations thresholds for high Lp(a) and treatment strategies remain undefined. This Korean position paper, developed by the Lp(a) Task Force of the Korean Society of Lipid and Atherosclerosis, presents an evidence-based summary of the pathophysiology, clinical relevance, and therapeutic landscape surrounding Lp(a), with a focus on Korean-specific data. It reviews the genetic architecture of Lp(a), ethnic variability in concentrations, and its mechanistic roles in inflammation, thrombosis, and calcification. Based on large Korean cohorts, a 3-tiered classification is proposed of normal (<30 mg/dL), borderline high (30-49 mg/dL), and high (≥50 mg/dL), harmonizing global thresholds with local data. The document also highlights the limitations of current Lp(a) assays in Korea, and calls for standardized, isoform-insensitive testing. Novel therapeutics, including antisense oligonucleotides, small interfering RNAs, and small molecular inhibitors, have shown promising Lp(a)-lowering effects, with multiple phase 3 trials currently ongoing, or in planning. Given the unmet clinical need, the paper recommends incorporating Lp(a) into cardiovascular risk assessment, and calls for Korean-specific longitudinal studies, national screening strategies, and participation in clinical trials. These efforts will help clarify Lp(a)-associated risk in Korean patients and guide the adoption of future targeted therapies. Show less
Ultrasound (US)-guided supine percutaneous nephrolithotomy (PCNL) is increasingly being adopted. The aim of this study was to assess the safety of lower vs non-lower pole access (non-LPa) in supine US Show more
Ultrasound (US)-guided supine percutaneous nephrolithotomy (PCNL) is increasingly being adopted. The aim of this study was to assess the safety of lower vs non-lower pole access (non-LPa) in supine US-guided PCNL. This study was a retrospective cohort analysis of 228 patients who underwent single-access US-guided supine PCNL between March 2023 and June 2024 and were categorized into lower (n = 162), interpolar (n = 42), and upper pole (n = 21) access categories. Baseline demographics, stone characteristics, and intraoperative details were analyzed and compared between the groups. Safety outcomes, including 30-day postoperative total and major complications (based on Clavien-Dindo classification), as well as pain scores, were compared between lower pole access (LPa) and non-LPa. Baseline clinical and stone characteristics were comparable between the groups. Non-LPa was more frequently performed on the right side ( When performing US-guided supine PCNL, LPa has a superior safety profile, resulting in fewer major and total complications compared with non-LPa. Show less
G-protein-coupled receptors (GPCRs) are high-value therapeutic targets, yet antibody discovery remains limited by difficulties in preparing antigens that preserve native conformations. Here, we engine Show more
G-protein-coupled receptors (GPCRs) are high-value therapeutic targets, yet antibody discovery remains limited by difficulties in preparing antigens that preserve native conformations. Here, we engineered a native-like, full-length human LPA2 antigen by combining N-terminal P9* fused with amphipathic poly-γ-glutamate (APG) stabilization, affording an antigen suitable for the selection of antibodies with therapeutic efficacy. By screening a large synthetic human scFv library, we isolated an antagonistic antibody against LPA2 that bound LPA2 selectively over LPA1 (EC Show less
Endothelial lipase (EL) is a key regulator of high-density lipoprotein (HDL) metabolism. Many aspects of EL function remain incompletely understood due to challenges in purifying active EL. This study Show more
Endothelial lipase (EL) is a key regulator of high-density lipoprotein (HDL) metabolism. Many aspects of EL function remain incompletely understood due to challenges in purifying active EL. This study identifies apolipoprotein J (ApoJ) as a novel chaperone for EL, crucial for its solubility and activity. Using an optimized purification protocol that yields active EL, we discovered that ApoJ consistently co-purifies with EL, maintaining its activity. We further show that knocking down ApoJ decreases the activity of EL. We demonstrate that ApoJ interacts with EL via its hydrophobic lid and tryptophan loop regions, and that mutating these regions abolishes the effect of ApoJ on the solubility and activity of EL. We show that ApoJ, EL, and ApoA1 (the defining lipoprotein of HDL particles) colocalize in HDL particles in mouse plasma. However, we find that ApoJ is not a direct carrier for EL to HDL particles. Instead, our data suggest that ApoJ primarily serves to enhance EL activity through its role as a chaperone, even when incorporated into lipid substrates. Our findings suggest a model in which ApoJ protects EL in plasma and enhances its hydrolysis of lipoprotein substrates. We propose that ApoJ is an accessory protein for EL, analogous to GPIHBP1 for LPL and co-lipase for PL. Further study of the interaction between EL and ApoJ will promote a better understanding of HDL metabolism. Show less
Increased fasting and postprandial triglyceride levels are risk factors for cardiovascular disease (CVD). Partially metabolized triglyceride-rich lipoproteins (TRLs) termed remnants are created when i Show more
Increased fasting and postprandial triglyceride levels are risk factors for cardiovascular disease (CVD). Partially metabolized triglyceride-rich lipoproteins (TRLs) termed remnants are created when intestinally-derived chylomicrons and liver secreted very low density lipoproteins (VLDLs) interact with lipoprotein lipase (LpL) situated on the luminal surface of capillary endothelial cells. Higher circulating remnant levels have been implicated as the reason for the relationship between TRL levels and CVD. We hypothesized that nascent lipoproteins not only remnants are atherogenic. To test this, we created mice with induced whole-body lipoprotein lipase (LpL) deficiency combined with LDL receptor (LDLR) deficiency. On an atherogenic Western-type diet (WD), male and female mice with induced global LpL deficiency (iLpl Show less
The effects of ovomucoid (OVM), a by-product of egg white, and its hydrolysates on adipocyte differentiation and lipid accumulation were investigated. The OVM hydrolyzed using Alcalase® and pepsin was Show more
The effects of ovomucoid (OVM), a by-product of egg white, and its hydrolysates on adipocyte differentiation and lipid accumulation were investigated. The OVM hydrolyzed using Alcalase® and pepsin was named AH and PH, respectively. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis analysis revealed significant changes in molecular weight of both hydrolysates, with AH showing a higher degree of hydrolysis. AH exhibited a more pronounced inhibitory effect on fat accumulation than PH. In in vitro experiments, AH and PH suppressed lipid accumulation during 3T3-L1 adipocyte differentiation, with AH inhibiting lipid accumulation most effectively. Oil red O staining and triglyceride measurements revealed lipid reduction in AH-treated cells, indicating that AH plays a major role in preventing lipid accumulation in adipocytes. In addition, AH inhibited the expression of lipid transcription factors (CCAAT/enhancer-binding protein alpha (C/EBP-α), peroxisome proliferator-activated receptor gamma (PPAR-γ), and sterol regulatory element-binding proteins (SREBP-1c)), adipogenesis-related factors (fatty acid synthase (FAS) and ACC1), insulin-related factors (insulin receptor substrate (IRS2) and protein kinase B (AKT2)), and lipolysis-related factors (glycerol-3-phosphate acyltransferase (GPAT), CD36, and lipoprotein lipase (LPL)) in a concentration-dependent manner. Specifically, the effect of AH was most pronounced in the early stages of adipocyte differentiation, where it activated AMPK early to associate energy homeostasis and downregulate genes important for cell cycle and lipid formation. This study suggests that OVM hydrolysates prepared using Alcalase® may contribute to the development of new strategies for the obesity treatment market. Show less
Fusion genes are major drivers of acute leukemia. Conventional diagnostics are limited in detecting the diverse fusions included in recently updated acute leukemia classifications. We evaluated the fu Show more
Fusion genes are major drivers of acute leukemia. Conventional diagnostics are limited in detecting the diverse fusions included in recently updated acute leukemia classifications. We evaluated the fusion detection performance of RNA sequencing (RNA-seq) compared with that of conventional diagnostics in patients with acute leukemia. We retrospectively obtained the data of 101 patients with acute leukemia who underwent conventional diagnostics (i.e., karyotyping, FISH, or multiplex reverse transcription PCR) at diagnosis at Samsung Medical Center, Seoul, Korea, between September 2022 and September 2023. Whole RNA-seq was performed using the Illumina Stranded mRNA Prep kit (Illumina, San Diego, CA, USA). The concordance, sensitivity, and specificity of RNA-seq for fusion gene detection were compared with those of conventional diagnostics. RNA-seq helped identify 52 fusion genes in 51 (50.5%) of 101 patients, with detection rates of 40.7%, 70.3%, 37.5%, and 50% in acute myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, and mixed-phenotype acute leukemia, respectively. RNA-seq showed 83.3% sensitivity and 80.8% concordance with conventional diagnostics; it missed eight fusions, likely because of low transcript abundance or enhancer hijacking. RNA-seq also helped clarify three previously unspecified rearrangements and detected 12 fusions (21.4%) in 56 cases that tested negative with conventional diagnostics, including four novel ( This was the first study to evaluate the performance of whole RNA-seq in fusion detection in patients with acute leukemia in Korea. Incorporating RNA-seq into diagnostic workflows may facilitate earlier and more precise therapeutic decisions and improve prognostic assessment in patients with acute leukemia. Show less
Williams-Beuren Syndrome (WBS), a neurodevelopmental disorder caused by a heterozygous microdeletion at chromosome 7q11.23, is characterized by hypersociability and enhanced affective empathy. However Show more
Williams-Beuren Syndrome (WBS), a neurodevelopmental disorder caused by a heterozygous microdeletion at chromosome 7q11.23, is characterized by hypersociability and enhanced affective empathy. However, the specific genetic and neural mechanisms within the WBS locus underlying this elevated empathic response remain unknown. Here, we investigated empathy-related behaviors, including observational fear and allogrooming, in WBS mouse models harboring a deletion within the conserved syntenic region on mouse chromosome 5. We demonstrate that WBS mice exhibited emotional contagion and prosocial consolation behaviors comparable to their wild-type controls. Furthermore, WBS mice with single-gene deletions of the cortex-enriched genes Abhd11, Limk1, Mlxipl, and Stx1a also showed unaffected empathic freezing behavior. Collectively, our findings suggest that the enhanced empathic responsiveness reported in individuals with WBS may be influenced by reduced social inhibition toward others, while acknowledging that limitations of current rodent behavioral assays preclude definitive conclusions regarding primary neural mechanisms of empathy. Show less
Idiopathic hypogonadotropic hypogonadism (IHH) and Kallmann syndrome (KS) are rare reproductive disorders with known genetic heterogeneity. Using exome sequencing, our group previously reported the pr Show more
Idiopathic hypogonadotropic hypogonadism (IHH) and Kallmann syndrome (KS) are rare reproductive disorders with known genetic heterogeneity. Using exome sequencing, our group previously reported the prevalence of pathogenic and likely pathogenic (P/LP) variants in genes causing IHH/KS as the primary endpoint of our study. Here, we investigate the frequency of secondary findings (SF) to determine whether individuals with IHH/KS harbor an increased burden of P/LP variants in medically actionable genes (MAGs) defined by the American College of Medical Genetics and Genomics (ACMG). We analyzed exome sequencing data from 156 individuals with clinically confirmed IHH/KS. Variants were filtered for P/LP classification using ACMG guidelines across all 84 MAGs in ACMG SF v3.3. Sanger sequencing was used for orthogonal confirmation. The prevalence of MAG variants was compared to external control datasets from the U.K. Biobank (UKB, ~ 50,000 genomes) and the NIH eMERGE Network (~ 21,000 genomes), both based on the ACMG SF v2.0 59-gene list. Among 370,000 variants, 2 individuals (1.3%) carried validated P/LP variants in two distinct MAGs: SCN5A and MYBPC3. Genes 60-84, the additional 25 genes on the ACMG SF v3.3 list, yielded no additional variants. The prevalence of MAG variants in IHH/KS (1.3%) was not significantly different from UKB (2.0%) or eMERGE (2.5%) (OR vs. UKB: OR 0.64; 95% CI, 0.16-2.61; P = 0.57). The frequency of P/LP variants in MAGs among IHH/KS patients is comparable to the general population, suggesting that MAG variants are not common in IHH/KS in contrast to some other types of infertility. Show less
Snail (SNAI1), a central transcription factor driving epithelial-mesenchymal transition (EMT), is pivotal in cancer metastasis and tissue remodeling. Owing to its labile nature, Snail activity is tigh Show more
Snail (SNAI1), a central transcription factor driving epithelial-mesenchymal transition (EMT), is pivotal in cancer metastasis and tissue remodeling. Owing to its labile nature, Snail activity is tightly controlled by post-translational modifications that dictate its stability. Here this review summarizes how the ubiquitin-proteasome system orchestrates Snail degradation through coordinated phosphorylation and ubiquitination, mediated by diverse E3 ligases and regulated by kinases, acetyltransferases and deubiquitinases. These mechanisms dynamically adjust Snail levels in both the cytoplasm and nucleus, thereby modulating EMT outcomes. In parallel, emerging studies reveal that chaperone-mediated autophagy (CMA) provides an additional layer of regulation. Through recognition of KFERQ-like motifs, CMA selectively directs cytoplasmic Snail to lysosomes for LAMP2A-dependent degradation, functioning as a quality control system. Impairment of CMA leads to nuclear accumulation of Snail, enhancing its EMT-inducing and prometastatic potential. Together, the ubiquitin-proteasome system and CMA represent complementary, context-dependent axes that maintain Snail homeostasis. Their disruption facilitates EMT activation and metastatic progression. By integrating recent findings, this review highlights the dual degradative control of Snail and its implications for cancer biology, providing a conceptual framework for therapeutic approaches aimed at restoring degradative balance and limiting metastasis. Show less
Colorectal cancer (CRC) is widely recognized for its high prevalence and significant mortality rates, and purine metabolism has been serving as a potential therapeutic target. However, purine metaboli Show more
Colorectal cancer (CRC) is widely recognized for its high prevalence and significant mortality rates, and purine metabolism has been serving as a potential therapeutic target. However, purine metabolism has not yet been validated as a prognostic marker through immunohistochemical analysis. In this study, we utilized a combination of bulk transcriptome analysis, immunohistochemistry (IHC), and single-cell RNA sequencing (scRNA-seq) to assess the clinical relevance of purine metabolism in CRC. Low expression levels of five purine metabolism-related genes-ADSL, APRT, ADCY3, NME3, and NME6-were associated with worse prognosis in CRC patient subgroups, including wild-type TP53, mutant TP53, and microsatellite-stable phenotypes. IHC-based validation showed that NME3 expression was an independent prognostic factor, whereas ADSL and NME6 expressions were associated with clinical variables in prediction of prognosis. Notably, NME3 expression predicted a high risk in patients with early-stage CRC, while ADSL and NME6 expressions were predictive in late-stage CRC. scRNA-seq analysis showed that four genes, excluding NME6, had low expression levels in epithelial cells at the late-stage CRC. Despite the reversible nature of purine metabolism reactions, we demonstrated a consistent directional expression of these five prognostic purine metabolism-related proteins in CRC tissues. We suggest that alterations in purine metabolism could serve as a clinically useful prognostic marker in CRC. Show less
This study investigated whether employment status moderates associations between baseline serum biomarkers and antidepressant remission at 12 weeks and 12 months. A prospective cohort of 1086 outpatie Show more
This study investigated whether employment status moderates associations between baseline serum biomarkers and antidepressant remission at 12 weeks and 12 months. A prospective cohort of 1086 outpatients diagnosed with depressive disorders received stepwise antidepressant therapy using a naturalistic, flexible treatment protocol. Fourteen serum biomarkers covering immune (hsCRP, TNF-α, IL-1β, IL-6, IL-4, IL-10), metabolic (leptin, ghrelin, total cholesterol), neuroplastic (BDNF), neurotransmitter (serotonin), endocrine (cortisol), and nutritional (folate, homocysteine) domains were analyzed at baseline. Employment-dependent biomarker associations with remission (Hamilton Depression Rating Scale ≤7) at 12 weeks and 12 months were evaluated using logistic regression with biomarker-by-employment interactions and stratified analyses, adjusting for relevant covariates. Higher serotonin levels significantly predicted 12-week remission exclusively among employed patients, with a significant employment interaction. At 12 months, lower leptin levels predicted remission specifically in employed patients, whereas lower TNF-α and higher BDNF levels predicted remission only in unemployed patients, each demonstrating significant employment interactions. Baseline serum biomarkers showed employment-dependent associations with antidepressant remission outcomes, highlighting serotonin's short-term relevance and leptin, TNF-α, and BDNF as longer-term indicators. Although exploratory, these findings suggest that integrating employment status with biomarker profiles may enhance clinical decision-making by identifying patients who are more or less likely to benefit from treatment across different phases of recovery. Replication in independent cohorts is needed to establish the clinical applicability of such employment-tailored, biomarker-informed strategies. Show less
Aging is associated with a progressive decline in both cognitive and physical function, and neuroinflammation and metabolic dysregulation often exacerbate this decline, particularly in older women. Th Show more
Aging is associated with a progressive decline in both cognitive and physical function, and neuroinflammation and metabolic dysregulation often exacerbate this decline, particularly in older women. This study investigated the effects of a 12-week intermittent combined exercise program on cognitive function, physical performance, and neurophysiological biomarkers in community-dwelling women aged 75 years and older. Forty participants were recruited from a local welfare center and randomly assigned to an exercise group (n=20) or a control group (n=20). The exercise group participated in three supervised sessions per week that integrated aerobic exercise, resistance exercise, functional exercise, and cognitive exercise. Cognitive domains (attention, language, and memory) were assessed using the Seoul Neuropsychological Screening Test-II. Physical function was assessed using the Geriatric Physical Fitness Test (chair stand, arm flexion, grip strength, and 6-min walk). Blood samples were analyzed to measure serum brain-derived neurotrophic factor (BDNF), interleukin (IL-6), tumor necrosis factor (TNF)-α, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG). Paired and independent Show less
Ischemia-reperfusion (I/R) injury, resulting from transient or permanent cerebral vessel occlusion, triggers oxidative stress, neuroinflammation, and blood-brain barrier (BBB) disruption, leading to p Show more
Ischemia-reperfusion (I/R) injury, resulting from transient or permanent cerebral vessel occlusion, triggers oxidative stress, neuroinflammation, and blood-brain barrier (BBB) disruption, leading to progressive neuronal damage and cognitive decline. The hippocampus, due to its high metabolic demand and susceptibility to oxidative stress, is particularly vulnerable to I/R-induced injury. This study evaluated the neuroprotective effects of α-lipoic acid (α-LA), a potent antioxidant, using bilateral common carotid arteries occlusion/reperfusion (BCCAO/R) mouse model and an oxygen-glucose deprivation/reoxygenation in vitro model. In BCCAO/R mice, α-LA improved spatial memory without affecting motor activity and restored hippocampal tight junction proteins (Claudin-5 and Occludin) and antioxidant enzyme expression, indicating BBB stabilization and oxidative stress reduction. Although synaptic proteins (BDNF and PSD-95) were not restored, cognitive improvements suggest alternative protective mechanisms. In HT22 cells, α-LA decreased intracellular reactive oxygen species levels, enhanced viability, and inhibited apoptosis via decreased PARP cleavage and caspase-3 activation. These protective effects were linked to the activation of the Nrf2/ARE signaling pathway and the upregulation of its downstream antioxidant targets. Overall, α-LA demonstrated marked neuroprotective effects in ischemic models by reducing oxidative stress, preserving BBB integrity, and restoring hippocampal function, positioning it as a promising therapeutic candidate for ischemic brain injury. Show less
Alzheimer's disease (AD) is a progressive neurodegenerative disease, characterized by the accumulation of amyloid beta (aβ) plaques and neurofibrillary tangles, along with progressive deterioration of Show more
Alzheimer's disease (AD) is a progressive neurodegenerative disease, characterized by the accumulation of amyloid beta (aβ) plaques and neurofibrillary tangles, along with progressive deterioration of cognitive function. AD is the most common form of dementia and affects over 55 million people worldwide. Current treatments for AD are symptomatic-based rather than curative, which calls for the development of new therapeutic strategies. Stem cell therapy has shown promising results for neurodegenerative diseases, including AD. Brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin receptor kinase B (TrkB), and their downstream signalling cascades play crucial role in modulating neuronal survival, development and synaptic plasticity, which are vital for cognitive functioning, and this pathway is dysregulated in AD. While the BDNF/TrkB signalling pathway dysregulation and stem cell therapy are each widely studied in AD, the interplay between those two remains underexplored. This review focuses on the mechanistic insights of the BDNF/TrkB signalling pathway in normal physiological condition and AD, along with the effects of stem cell therapy on the pathway and its downstream cascades. The findings highlight the therapeutic outcomes in increasing BDNF/TrkB levels and functions, restoring synaptic plasticity, modulating downstream substrates activities and improving cognitive functions. In addition, challenges, limitations and future directions of stem cell therapy are discussed, underscoring the therapeutic benefits of this therapy for AD by modulating the BDNF/TrkB signalling pathway. Show less
We aimed to delineate strategies for improved management of brain metastases (BM) in breast cancer by investigating the estrogen-related BDNF–TrkB pathway within the tumor microenvironment. Surgical s Show more
We aimed to delineate strategies for improved management of brain metastases (BM) in breast cancer by investigating the estrogen-related BDNF–TrkB pathway within the tumor microenvironment. Surgical specimens of BM tissues from breast cancer patients were analyzed using multiplex immunohistochemistry. Expression patterns of BDNF, TrkB, and phospho-AKT were assessed separately in tumor and stromal compartments and compared across molecular subtypes. Clinical data were reviewed to identify factors associated with brain-specific progression-free survival (BPFS) and overall survival (BOS). Endocrine therapy following BM diagnosis was independently associated with prolonged brain-specific survival among luminal patients (HR for BPFS and BOS, 0.22 and 0.19; Survival after BM was influenced by both tumor characteristics and treatment modalities. In luminal disease, endocrine therapy and estrogen depletion may exert anti-tumor activity through inhibition of the BDNF–TrkB pathway. These findings provide novel insight into the biology of breast cancer brain metastases and suggest a rationale for further validation in multicenter studies. Not applicable. The online version contains supplementary material available at 10.1007/s11060-025-05393-3. Show less
The mechanism(s) by which exercise training induces multiple beneficial effects for Alzheimer's disease (AD) patients are not well-understood. This study aimed to examine the link between the brain-de Show more
The mechanism(s) by which exercise training induces multiple beneficial effects for Alzheimer's disease (AD) patients are not well-understood. This study aimed to examine the link between the brain-derived neurotrophic factor (BNDF)-tropomyosin receptor kinase B (TrkB) signaling complex and the beneficial effects of exercise training on cognitive impairment and neuropathology due to AD. At 4 months of age, twenty triple transgenic mice of AD (3x-Tg AD) were randomly assigned to either an AD control (n = 10) or AD exercise (n = 10) group. In parallel, twenty wild-type mice were randomly assigned to either a wild-type control (n = 10) or wild-type exercise (n = 10) group. After 20 weeks of treadmill running, the Morris water maze test was performed, and the mice were then sacrificed for biochemical analyses of plasma and brain tissues. The results indicated that 20 weeks of treadmill running upregulated markers of the BDNF-TrkB signaling complex and mitigated AD neuropathology, along with full recovery from AD-like cognitive impairments. Exercise training also decreased inflammatory cytokines, increased anti-inflammatory cytokines, shifted microglia and astrocytes toward anti-inflammatory phenotypes, improved mitochondrial function, reduced markers of myelin damage, and reduced apoptotic neuronal cell death. In summary, our study findings suggest that exercise training-induced recovery of AD-like cognitive impairments and mitigation of AD neuropathologic biomarkers are associated with modulation of the BDNF-TrkB complex and downstream signaling pathways in 3xTg-AD mice. Show less
Transcranial direct current stimulation (tDCS) is a promising non-invasive intervention for mild cognitive impairment (MCI). This prospective study investigated the relationship between optimized elec Show more
Transcranial direct current stimulation (tDCS) is a promising non-invasive intervention for mild cognitive impairment (MCI). This prospective study investigated the relationship between optimized electrical field (EF) strength of tDCS and white matter (WM) microstructural changes in 55 individuals with MCI. Magnetic resonance imaging (MRI)-based computational modeling was used to optimize EF strength targeting the left dorsolateral prefrontal cortex (DLPFC). Diffusion tensor imaging (DTI) assessed WM integrity through fractional anisotropy (FA), mean diffusivity (MD), and radial diffusivity (RD). Higher EF strength was significantly associated with increased FA and reduced MD and RD in specific left-lateralized tracts, including the anterior thalamic radiation, corticospinal tract, inferior fronto-occipital fasciculus, and inferior longitudinal fasciculus. These EF-dependent WM changes were moderated by Alzheimer's disease (AD)-related factors. Greater WM plasticity was observed in Aβ-positive individuals, APOE ε4 non-carriers, and BDNF Met non-carriers. Moreover, APOE ε4 status significantly moderated the relationship between EF strength and executive function; in non-carriers, stronger EF strength was associated with improved Stroop performance, potentially reflecting enhanced WM integrity in the right superior longitudinal fasciculus. However, no significant associations were observed between EF-sensitive tracts and short-term cognitive changes in the full sample, suggesting that structural modifications may precede functional improvements or require longer follow-up. These findings emphasize the importance of individual AD-related factors in shaping neuromodulatory responses. They also support the need for longitudinal, sham-controlled studies to clarify the clinical implications of EF strength in personalized tDCS for MCI. Show less
This study aimed to determine whether a history of childhood abuse (CA) and baseline serum brain-derived neurotrophic factor (sBDNF) levels predict remission at 12 weeks and 12 months in patients with Show more
This study aimed to determine whether a history of childhood abuse (CA) and baseline serum brain-derived neurotrophic factor (sBDNF) levels predict remission at 12 weeks and 12 months in patients with depressive disorders, and to examine potential interactions between these factors. A total of 1,086 patients with depressive disorders, participating in a naturalistic, stepwise antidepressant treatment study, were assessed at baseline. CA was evaluated using the Nemesis Childhood Trauma Interview, and sBDNF levels were measured. Remission was defined as a Hamilton Depression Rating Scale score of ≤ 7. Logistic regression analyses examined the independent and interactive effects of CA and sBDNF on remission outcomes, adjusting for relevant covariates. Low baseline sBDNF independently predicted poorer remission at 12 months (p = 0.045) but not at 12 weeks (p = 0.720). In adjusted analyses, CA alone did not significantly predict remission at either time point (all p > 0.05). However, patients who had both a CA history and low baseline sBDNF showed significantly lower remission rates at 12 weeks (p = 0.018) and 12 months (p = 0.009), indicating a significant interaction between these factors. These findings underscore the importance of integrating psychosocial and biological factors in personalized depression treatment. Routine screening for childhood trauma, combined with assessment of sBDNF levels, may help identify high-risk patients needing targeted interventions. Further prospective research is necessary to validate these findings. Show less
The Gold Coast criteria permit diagnosis of amyotrophic lateral sclerosis (ALS) even without upper motor neuron (UMN) signs. However, whether ALS patients with UMN signs (ALSwUMN) and those without (A Show more
The Gold Coast criteria permit diagnosis of amyotrophic lateral sclerosis (ALS) even without upper motor neuron (UMN) signs. However, whether ALS patients with UMN signs (ALSwUMN) and those without (ALSwoUMN) share similar characteristics and prognoses remains unclear. This study compared clinical features, disease progression, electrophysiological findings, biomarker profiles, imaging parameters, and survival between these groups. ALS patients diagnosed according to the Gold Coast criteria were classified into ALSwUMN (n = 51) and ALSwoUMN (n = 20) groups. We evaluated clinical data, motor evoked potentials (MEP), and serum biomarkers, including cardiac Troponin T, neurofilament light chain, glial fibrillary acidic protein, and brain-derived neurotrophic factor. Imaging parameters, including cortical thickness and white matter volume, were also evaluated. Survival was analyzed using the Kaplan-Meier method. The groups showed broadly similar clinical features, disease progression, and biomarker profiles. Abnormal MEPs were more frequent in ALSwUMN (94.0%) than in ALSwoUMN (63.2%, p = 0.017). Both groups demonstrated cortical thinning in the precentral and entorhinal regions compared to healthy controls. ALSwUMN exhibited thinning in the lateral orbitofrontal, insular, and temporal pole regions, while ALSwoUMN showed thinning in the pars opercularis. White matter volume was reduced in both groups in the thalamus, cerebellum, and amygdala, with additional brainstem atrophy in ALSwUMN. No significant survival difference was observed. Despite minor distinctions in electrophysiological and imaging findings, ALSwoUMN had overall comparable clinical profiles and outcomes to ALSwUMN. These findings support recognizing ALSwoUMN within the ALS spectrum under the Gold Coast criteria. Show less
G protein-coupled receptors (GPCRs) play key roles in physiology and are central targets for drug discovery and development, yet the design of protein agonists and antagonists has been challenging as Show more
G protein-coupled receptors (GPCRs) play key roles in physiology and are central targets for drug discovery and development, yet the design of protein agonists and antagonists has been challenging as GPCRs are integral membrane proteins and conformationally dynamic. Here we describe computational Show less
The melanocortin receptor 4 (MC4R) plays a key role in the CNS regulation of metabolism. In addition to its role within the hypothalamus, other brain areas, including the dorsal raphe nucleus (DRN), e Show more
The melanocortin receptor 4 (MC4R) plays a key role in the CNS regulation of metabolism. In addition to its role within the hypothalamus, other brain areas, including the dorsal raphe nucleus (DRN), express MC4R. However, the identity and role of these neurons in metabolism regulation are not fully understood. We performed studies to address these questions. We generated Mc4r-cre;Vgat-FlpO and Mc4r-cre;Vglut2-FlpO mice to determine the contribution of these MC4R neuronal populations in DRN. We then chemogenetically activated or inhibited the GABAergic and glutamatergic populations of MC4R. Finally, we selectively deleted MC4R from these two neuronal populations and studied the impact on whole-body metabolism. We found that about 60% of DRN MC4R neurons are GABAergic (Vgat), while only about 20% are glutamatergic (Vglut2). Most of the projections onto DRN neurons originated from the arcuate nucleus (ARC)-POMC neurons, and only a small input from the nucleus of the solitary tract (NTS)-POMC neurons was identified. Significant projections of DRN MC4R/Vgat neurons were observed in the paraventricular nucleus of the hypothalamus (PVN). Chemogenetic activation or inhibition of MC4R/Vgat neurons increased or inhibited food intake, respectively. No effects were observed when the same approach was used in MC4R/Vglut2 neurons. Furthermore, only chemogenetic manipulation of the MC4R/Vgat neurons affected anxiety-like behavior, which was associated with changes in serotonin staining in the DRN. Finally, MC4R-selective deletion in Vgat but not Vglut2 neurons affected whole-body metabolism. These findings suggest that DRN MC4R/Vgat neurons receiving projections from the ARC POMC neurons and projecting to the hypothalamic PVN play a role in metabolism regulation. In addition, this same DRN neuronal subpopulation affects anxiety-like behavior by modulating DRN serotonin neurons. Show less
Genes associated with body mass index (BMI), including FTO rs9939609,MC4R rs17782313, and BDNF rs6265, may influence BMI and regulate energy metabolism. While previous studies have explored health-rel Show more
Genes associated with body mass index (BMI), including FTO rs9939609,MC4R rs17782313, and BDNF rs6265, may influence BMI and regulate energy metabolism. While previous studies have explored health-related behavior changes, few have investigated both biochemical and behavior changes resulting from perceived genetic risk. This study investigated whether recognizing BMI-related genes affects health-related behaviors and alters blood metabolite levels. Normal and overweight adults aged 25-35 years (n = 100) were randomly assigned to an intervention group (n = 65) informed about BMI-related genetic information (FTO rs9939609, MC4R rs17782313, BDNF rs6265) and an uninformed group (n = 35, CON). The intervention group was further divided into Intervention-high risk (IHR, n = 36) and intervention-low risk (ILR, n = 29) subgroups. Dietary intake and physical activity (PA) were assessed using a 3-day dietary record and the IPAQ-short form. Blood metabolites were analyzed through multivariate analyses to identify significant differences among the groups, with measurements taken at baseline, 3 months, and 6 months. The IHR group exhibited increased dietary fat and fast foods intake, along with enhanced vigorous and moderate PA. Six metabolites were selected as biomarkers that were distinguishable among groups, and the relative serum cholesterol levels significantly decreased in the IHR group at 3 months. These results demonstrate that recognizing the BMI-associated genetic risk resulted in a short-term increase in PA but did not improve dietary intake. Increased PA was significantly associated with reduced cholesterol concentration, suggesting the clinical importance of physical activity in the genetically at-risk group. This study was reviewed and approved by the Seoul National University Institutional Review Board (IRB #1901/001-004) and registered on the Clinical Research Information Service (CRIS), KCT0004650 ( https://cris.nih.go.kr/cris/search/detailSearch.do /14091, 2020/01/28). Show less
Myunghyun Cheon, Woonhee Kim, ChiHye Chung · 2025 · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · added 2026-04-24
Central melanocortin signaling plays a critical role in maintaining energy homeostasis by regulating energy intake and expenditure, with impairment of this system closely related to metabolic diseases Show more
Central melanocortin signaling plays a critical role in maintaining energy homeostasis by regulating energy intake and expenditure, with impairment of this system closely related to metabolic diseases such as obesity. Among melanocortin receptor subtypes, melanocortin receptor 4 (MC4R) is the primary mediator of these effects within the central nervous system. Accumulating evidence suggests that MC4R contributes to stress-induced disruptions in feeding behavior and energy homeostasis. However, the precise neural mechanisms by which stress alters MC4R activity remain incompletely understood. In this study, we compared brain-wide c-Fos expression patterns induced by two distinct stress paradigms: lipopolysaccharide (LPS)-induced inflammatory stress and restraint stress in male mice, and further examined the involvement of MC4R-expressing (MC4R Show less